The STOPCoV study, sponsored by the University Health Network in Toronto, aims to assess the safety and immunogenicity of COVID-19 vaccines in older adults (70 years and over) compared to a younger cohort (30-50 years). With an enrollment of 1,286 participants, this study addresses a critical gap in understanding vaccine efficacy across age groups, particularly in older populations who are at higher risk for severe COVID-19 outcomes. The findings could influence vaccine recommendations and public health policies, potentially impacting market dynamics for COVID-19 vaccines. Given the ongoing demand for vaccine data, this study may also attract interest from pharmaceutical companies looking to bolster their vaccine portfolios or develop new formulations tailored for older adults.